Exemptia 40mg Injection

• Rheumatoid arthritis
• Polyarticular juvenile idiopathic arthritis
• Enthesitis-related arthritis
• Ankylosing spondylitis
• Axial spondyloarthritis without radiographic evidence of ankylosing spondylitis
• Psoriatic arthritis
• Plaque psoriasis
• Hidradenitis suppurativa
• Crohn’s disease
• Ulcerative colitis
• Non-infectious uveitis​
  

​Exemptia 40mg Injection can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stays for prolonged period of time.

Common side effects include:

• Injection site reactions

• Rash

• Headache

• Sinusitis

• Upper respiratory infections

• Fever

Serious

• Heart problems

• Abnormal heart beat

• Severe skin reactions

• Abnormal blood count values

• Liver injury

• Bone problems

• Infections

• ​The recommended dose of Exemptia 40mg Injection  may vary according to the type of disease, as well as age, weight, and other health factors of the patients.
• It should be given under the skin (subcutaneously) by a doctor or experienced nurse.
• Don't self- administer the injection and don't double the dose to compensate for the missed dose.​

• Alcohol: Avoid the consumption of alcohol while taking Exemptia 40mg Injection    , as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms.

• Pregnancy:  Do not take Exemptia 40mg Injection  without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.

• Breastfeeding:  Breastfeeding women should discuss the potential risks and benefits of the Exemptia 40mg Injection with their healthcare provider before starting treatment.

• Driving:  Exemptia 40mg Injection   may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.

• Kidney: Share your medical history with the doctor before starting the Exemptia 40mg Injection  . Do not take it without consulting a doctor if you have any kidney related issue.

• Liver: Share your medical history with the doctor before starting the Exemptia 40mg Injection. Do not take it without consulting a doctor if you have any liver related issue.

If you miss a dose of Adalimumab injection, contact your health professional as soon as possible. Try not to miss or skip your dosage of Exemptia injection.

What is Exemptia 40mg Injection?

Exemptia 40mg Injection is used for the treatment of various conditions (rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis).

Does Exemptia 40mg Injection cause Any Side Effects?

Some common side effects of Exemptia 40mg Injection are nausea, weakness, pale skin, irregular heartbeat, difficulty in breathing, vomiting, fever, etc.

What Happens If I overdose on Exemptia 40mg Injection?

It is advisable to consult your medical practitioner in case of an overdose of Exemptia 40mg Injection.

Is it Safe to Use Exemptia 40mg Injection During Pregnancy?

​The use of Exemptia injection is not recommended in pregnancy.

Can a patient with liver or kidney related issue take Exemptia 40mg Injection?

Patients with liver or kidney related issues should avoid taking Exemptia injection without consulting the doctor.

 At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Navarro‐Sarabia, F., Ariza‐Ariza, R., Hernandez‐Cruz, B., & Villanueva, I. (2005). Adalimumab for treating rheumatoid arthritis. The Cochrane Database of Systematic Reviews, 2005(3), CD005113.

Lapadula, G., Marchesoni, A., Armuzzi, A., Blandizzi, C., Caporali, R., Chimenti, S., ... & Salvarani, C. (2014). Adalimumab in the treatment of immune-mediated diseases. International Journal of Immunopathology and Pharmacology, 27(1_suppl), 33-48.

Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., Stapel, S., Lems, W. F., Aarden, L., ... & Wolbink, G. J. (2007). Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the rheumatic diseases, 66(7), 921-926.

Kapoor, S., Kaushik, V. K., Jain, R., Rao, V. K. R., Gharia, M., et al. (2019). Real‑life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: Adalimumab Biosimilar Patient Registry data. ACR Open Rheumatology, 1(8), 480–484 - https://doi.org/10.1002/acr2.11067

Midha, Y., Kumar, N., Singhal, S., et al. (2023). Efficacy and safety of Exemptia™ (biosimilar adalimumab) in moderate-to-severe steroid-refractory ulcerative colitis: 24-week follow-up in a real-world setting. Biologics: Targets & Therapy (retrospective analysis). Patil, S. (2018). Low‑dose adalimumab biosimilar (ZRC‑3197) in the treatment of hidradenitis suppurativa. Indian Journal of Dermatology, Venereology and Leprology, 84(5), 745–747.